Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DURABOLIN vs QUINALAN
Head-to-head clinical comparison of therapeutic indices and safety profiles.
DURABOLIN (nandrolone phenpropionate) is an anabolic steroid that binds to androgen receptors, increasing protein synthesis and nitrogen retention, promoting muscle growth and bone density. It also stimulates erythropoietin production, increasing red blood cell mass.
Quinidine (the active ingredient in Quinalan) is a class Ia antiarrhythmic agent that binds to and blocks voltage-gated sodium channels in cardiac myocytes, prolonging the action potential duration and effective refractory period. It also has vagolytic effects and blocks potassium channels.
Adjunctive therapy to promote weight gain after severe illness, surgery, or trauma,Osteoporosis (off-label),Anemia of renal failure (off-label),HIV/AIDS wasting syndrome (off-label)
Treatment of atrial fibrillation and atrial flutter to maintain sinus rhythm,Treatment of ventricular arrhythmias (e.g., ventricular tachycardia)
100-200 mg intramuscularly every 1-2 weeks for testosterone replacement; for wasting syndromes, 50-100 mg intramuscularly weekly.
10 mg orally once daily, may increase to 20 mg after 2 weeks if needed.
Terminal elimination half-life: 4-6 days (intramuscular depot), reflecting slow release from injection site and enterohepatic recirculation; clinical steady-state achieved after 3-6 weeks.
Terminal half-life: 12 hours (range 10-14) in normal renal function; prolonged to 24-30 hours in severe renal impairment (Cr Cl <30 m L/min).
Hepatic metabolism via reduction and conjugation; primarily excreted in urine as metabolites (e.g., 19-norandrosterone and 19-noretiocholanolone).
No specific guidelines; use caution in severe impairment (Cr Cl <30 m L/min) due to fluid retention and potential edema.
GFR > 30 m L/min: no adjustment; GFR 10-30 m L/min: reduce dose to 5 mg once daily; GFR < 10 m L/min: not recommended.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use due to risk of cholestasis and hepatotoxicity.
Anabolic steroids may cause peliosis hepatis, liver cell tumors, and blood lipid changes associated with increased cardiovascular risk. Prolonged use can lead to azoospermia, oligospermia, and impotence. Not approved for enhancing athletic performance.
DURABOLIN (nandrolone) is contraindicated in pregnancy. Androgens can cause virilization of the female fetus. First trimester exposure risks clitoromegaly, labial fusion, and urogenital sinus abnormalities. Second and third trimester exposure may lead to clitoromegaly and advanced bone age. Fetal growth restriction and preterm birth are also reported.
First trimester: Not recommended due to potential teratogenicity (animal studies show skeletal and visceral malformations). Second and third trimesters: May cause fetal tachycardia, hypoglycemia, and reduced placental perfusion. Risk-benefit assessment required.
Durabolin (nandrolone phenylpropionate) is an injectable anabolic steroid with a shorter ester than nandrolone decanoate, allowing for faster onset and offset. Monitor liver function tests and lipid profiles, as it can cause HDL suppression and LDL elevation. Use with caution in patients with pre-existing cardiac, hepatic, or renal disease. Suppresses endogenous testosterone; consider testosterone replacement during and after therapy. Detectable on doping tests for up to 18 months in athletes; educate accordingly.
QUINALAN is a combination antimalarial containing quinine and a 4-aminoquinoline; monitor for cinchonism (tinnitus, headache, visual disturbances) and QT prolongation. Avoid in G6PD deficiency due to hemolytic risk. Therapeutic drug monitoring recommended for quinine levels (target 5-15 mg/L).
No interactions on record
No interactions on record
DURABOLIN and QUINALAN are distinct pharmacological agents. DURABOLIN belongs to the Anabolic Androgenic Steroid class and is primarily used for Adjunctive therapy to promote weight gain after severe illness, surgery, or traumaOsteoporosis (off-label)Anemia of renal failure (off-label)HIV/AIDS wasting syndrome (off-label). QUINALAN belongs to the Antiarrhythmic (Class Ia) class and is primarily used for Treatment of atrial fibrillation and atrial flutter to maintain sinus rhythmTreatment of ventricular arrhythmias (e.g., ventricular tachycardia). Their specific mechanisms of action, pharmacokinetic characteristics, and side effects differ.
The maternal-fetal safety profiles of these drugs differ. DURABOLIN carries a safety status of Category C, whereas QUINALAN safety is classified as Category C. Consult a board-certified physician or healthcare specialist to establish an accurate, individualized pregnancy risk assessment before starting either therapy.
Primarily hepatic via CYP3A4, with some contribution from CYP2C19; also undergoes N-oxidation and conjugation.
Primarily renal: 90% as metabolites (glucuronide and sulfate conjugates), 10% unchanged; negligible biliary/fecal elimination.
Renal: 60% unchanged; Biliary/fecal: 30% as metabolites; 10% other.
85-95% bound to sex hormone-binding globulin (SHBG) and albumin; high affinity for SHBG, reducing free active fraction.
92% bound, primarily to albumin.
4-6 L/kg, indicating extensive tissue distribution, particularly to skeletal muscle, bone, and prostate.
0.6 L/kg (range 0.4-0.8), indicating distribution into total body water.
Intramuscular: ~100% (depot formulation); oral: negligible (<1% due to first-pass hepatic metabolism).
Oral: 75% (range 70-80%) due to moderate first-pass metabolism.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose to 5 mg once daily; Child-Pugh C: contraindicated.
Not recommended in children due to premature epiphyseal closure and potential virilization; limited data, use only under expert supervision for delayed growth.
Weight < 30 kg: 0.3 mg/kg orally once daily, max 10 mg; Weight ≥ 30 kg: 10 mg orally once daily, max 20 mg.
Initiate at lowest effective dose (e.g., 50 mg IM every 2 weeks) due to increased risk of prostatic hypertrophy, fluid retention, and polycythemia.
Initiate at 5 mg orally once daily, titrate cautiously due to increased risk of hypotension and renal impairment.
None
Risk of hepatic dysfunction, peliosis hepatis, hepatocellular carcinoma, hyperlipidemia, cardiovascular disease, edema, hypertension, glucose intolerance, premature closure of epiphyseal growth plates in children, virilization in women, and prostate hypertrophy in men. Monitor liver function, lipid profile, and hematocrit. Use with caution in patients with cardiac, renal, or hepatic disease.
Known hypersensitivity to nandrolone or any component, pregnant or breastfeeding women, men with carcinoma of the breast or prostate, nephrotic syndrome, hypercalcemia, severe hepatic dysfunction, and patients with a history of myocardial infarction or coronary artery disease.
No specific food interactions reported. However, maintain a balanced diet low in saturated fats and sodium to mitigate adverse lipid and cardiovascular effects. Avoid excessive alcohol consumption due to hepatotoxicity risk.
Avoid grapefruit juice as it may increase quinine levels and prolong QT interval. High-tyramine foods (aged cheese, cured meats) can potentiate hypertensive effects. Maintain adequate hydration to prevent crystalluria.
Nandrolone is excreted into breast milk. The milk-to-plasma ratio is not established. Androgens may suppress lactation and cause virilization in the nursing infant. Use during breastfeeding is contraindicated.
Excreted into breast milk; M/P ratio unknown. Potential for infant hypoglycemia and tachycardia. Contraindicated during breastfeeding if alternatives exist.
No dosing adjustments are applicable as DURABOLIN is contraindicated in pregnancy. No pharmacokinetic data in pregnancy to guide dose modification.
Increased plasma volume and renal clearance in pregnancy may reduce drug exposure; no established dosing guidelines. Consider therapeutic drug monitoring if available; adjust to maintain efficacy without exceeding safe fetal levels.
This medication is for intramuscular injection only; do not inject intravenously.,Report signs of liver problems (jaundice, dark urine, abdominal pain) or heart issues (chest pain, shortness of breath) immediately.,May cause changes in libido, acne, hair growth, or voice deepening; these may be irreversible.,Regular blood tests are required to monitor liver function, cholesterol, and blood count.,Do not share needles; proper disposal of used syringes is mandatory.,Avoid use during pregnancy and breastfeeding.,May interact with blood thinners (e.g., warfarin) and oral antidiabetics; advise dose adjustments.
Take with food or milk to reduce gastrointestinal upset.,Complete the full course even if feeling better.,Report symptoms of cinchonism: ringing in ears, headache, blurred vision, or dizziness.,Avoid driving or operating machinery if vision or hearing is affected.,Inform provider if you have glucose-6-phosphate dehydrogenase (G6PD) deficiency.